Alan Hippe - Roche Holding CFO
| ROGN Stock | MXN 4,026 14.40 0.36% |
CFO
Dr. Alan Hippe was Member of the Corporationrationrate Executive Committee, Chief Financial Officer and Information Technology Officer at Roche Holding Ltd since April 1, 2011. Between 1993 and 1996 Dr. Hippe was Research Assistant and Teaching Assistant at the Universities of Mainz and Mannheim. In 1996 he joined AVECO Holding AG as Head of group controlling and IT systems. He served as Member of the Executive Board of Continental AG from 2002 to 2009. In April 2009 he was appointed Chief Financial Officer and Member of Executive Board of ThyssenKrupp AG. since 2011.
| Age | 56 |
| Tenure | 13 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | CFO Age | ||
| Francis Shammo | Verizon Communications | 54 | |
| Quint Turner | Air Transport Services | 60 | |
| Edouard Boudrant | FibraHotel | 34 | |
| Theresa Wagler | Steel Dynamics | 53 | |
| Marc Katz | Burlington Stores | 52 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Member of the Corporate Executive Committee, Head of Group Human Resources | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, Member of the Corporate Executive Committee, COO Division Roche Pharmaceuticals | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, Member of the Corporate Executive Committee, CFO, Information Technology Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, Chairman of the Corporate Executive Committee, CEO, Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 5.83 T | |||
| Shares Outstanding | 693.89 M | |||
| Shares Owned By Institutions | 40.30 % | |||
| Price To Earning | 421.29 X | |||
| Price To Book | 9.80 X | |||
| Price To Sales | 79.71 X |
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Roche Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |